An expert discusses interim safety findings from a phase 2 randomized study evaluating axatilimab in combination with ruxolitinib for patients with newly diagnosed chronic graft-versus-host disease, presented by Amandeep Salhotra, MD, of City of Hope National Medical Center.
Dr. Lorenzo Falchi presents primary phase 3 EPCORE FL-1 results showing that epcoritamab plus rituximab and lenalidomide significantly improves efficacy outcomes vs rituximab and lenalidomide alone in relapsed/refractory follicular lymphoma.
Four-year follow-up results from the Phase 3 CheckMate 9DW trial show that nivolumab plus ipilimumab continues to provide sustained overall survival and durable response benefits versus lenvatinib or sorafenib as first-line therapy for unresectable hepatocellular carcinoma. The combination demonstrated higher long-term survival rates and a higher complete response rate, with no new safety signals reported.
In this real-world retrospective study of patients with CLL/SLL treated at UCSF, outcomes with next-generation BTK inhibitors zanubrutinib and acalabrutinib were compared using adjusted analyses of time to next treatment and overall survival. Despite patients receiving zanubrutinib having more high-risk features and comorbidities, zanubrutinib was associated with a lower risk of starting subsequent therapy and a trend toward improved survival compared with acalabrutinib.
The RRO highlights that isatuximab combined with RVd as induction therapy produced deep and rapid responses in transplant-eligible patients with newly diagnosed multiple myeloma. The regimen was generally well tolerated with a favorable safety profile, and early molecular responses were observed in a meaningful proportion of patients.
Ryan Jacobs, MD discusses incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib.
Leyla Shune MD, discusses Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program.
Discover the latest insights on Revumenib's real-world effectiveness in treating acute myeloid leukemia, presented at ASH 2025.
Emily S. Ruiz, MD, MPH, FAAD discusses efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a pivotal open-label study with a median follow-up of ≥2 years.
Using data from the ALPINE trial, this analysis demonstrates that worsening patient-reported symptoms, particularly fatigue, insomnia, and nausea/vomiting, is significantly associated with increased risk of disease progression in patients with relapsed/refractory CLL/SLL.
This video details patient-reported outcomes from the DESTINY-Breast09 Phase 3 trial, comparing first-line treatments T-DXd + pertuzumab versus THP (taxane-based therapy) for HER2+ advanced/metastatic breast cancer.
Michael Wang, M.D. discusses Sonrotoclax (BGB-11417) monotherapy in patients with R/R MCL previously treated with a BTK inhibitor: results from a phase 1/2 study
Tracy I. George, MD discusses the effect of Bezuclastinib on the pathobiology of mastocytosis: changes in BM mast cells, Tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial
Constantine S. Tam, MD discusses long-term results of patients receiving Zanubrutinib in the Phase 3 ALPINE study confirm sustained benefit of Zanubrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 years of follow-up with the long-term extension.
Constantine S. Tam, MD discusses frontline treatment of Sonrotoclax (BGB-11417) + Zanubrutinib for CLL/SLL demonstrates high uMRD rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study.
Constantine S. Tam, MD, presents a modeled analysis estimating the number needed to treat (NNT) to prevent one progression or death when using zanubrutinib versus other covalent Bruton tyrosine kinase inhibitors (BTKis) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
Brian M. Shuch, MD, discusses the impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X).
Thomas Powles, MBBS, MRCP, MD discusses IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer.
Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.
Thomas Hutson, DO, PharmD, PhD, FACP presents the latest findings from the CLEAR trial on lenvatinib + pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma with or without bone metastases.
The presentation highlights results from the OptimUM-01 study evaluating darovasertib + crizotinib as first-line treatment for metastatic uveal melanoma, showing improved median overall survival (21.1 months) and higher response rates compared with historical standard therapies. The combination demonstrated a manageable safety profile, supporting its continued evaluation in the ongoing registrational OptimUM-02 trial.
Christian Marth, MD, PhD discusses long-term efficacy and safety results from KEYNOTE-775 and LEAP-001. Data include patients with advanced or recurrent endometrial cancer after prior systemic therapy. Follow-up duration was approximately 5 years for KEYNOTE-775 and 4 years for LEAP-001.
Tiffany Traina, MD, FASCO, highlights results from the phase 3 TROPION-Breast02 trial showing that datopotamab deruxtecan significantly improved progression-free and overall survival versus chemotherapy in patients with previously untreated triple-negative breast cancer who were not eligible for immunotherapy.
Misty D. Shields, MD, PhD, reviews primary findings from the IDeate-Lung01 trial, highlighting the promising systemic and intracranial efficacy and manageable safety profile of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer, including those with baseline brain metastases.
Summarize long-term results from the phase 2 EDGE-Gastric Arm A1 study evaluating domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + FOLFOX as first-line therapy for advanced HER2-negative gastric, GEJ, or esophageal adenocarcinoma. Key data shown include ORR, PFS, OS, and safety outcomes, demonstrating encouraging clinical activity and manageable toxicity, along with context regarding the ongoing phase 3 STAR-221 trial.
Sikander Ailawadhi, MD, reviews patient experience and satisfaction findings from the phase 3 IRAKLIA study comparing subcutaneous isatuximab via on-body injector with intravenous isatuximab in relapsed or refractory multiple myeloma.